As the next generation of multispecific therapies, antibody-drug conjugates, and combination therapies continues to develop, there is a growing focus on ensuring the safety and efficacy of these therapies. Safety and toxicity pose unique challenges among different therapeutic modalities. At Cambridge Healthtech Institute's 2nd annual Safety and Efficacy of Multispecific Antibodies, ADCs, and Combination Therapies conference, sessions will build upon past and present research to explore the field is addressing these challenges. The conference will compare and contrast different therapeutic modalities, and speakers from industry, academia, and the clinic will go over strategies for mitigating toxicity, managing combination therapies, reducing side effects, and closing disparities in access. This meeting will complement topics in multispecific antibody discovery and engineering for meeting unmet clinical needs